List view / Grid view
21 September 2016 | By Niamh Louise Marriott, Digital Content Producer
T-Guard has been shown to be well tolerated, with a manageable side effect profile and no severe infusion reactions in patients with acute GVHD...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
She will succeed Andrew Witty as GSK CEO, when he retires on 31st March 2017. She will be the first female CEO of a major global pharmaceuticals company...
20 September 2016 | By WHEATON®
New line of purpose-built, ready-to-sterilize, uniquely barcoded vials will be introduced at the American Association of Clinical Chemistry Annual Meeting...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
This study was the first in man Phase 1 clinical trial for an mGluR4 positive allosteric modulator. The randomised, double-blind, placebo controlled single and multiple ascending dose studies were designed to assess safety and tolerability of PXT002331 dosed orally...
20 September 2016 | By Edinburgh Instruments
Research in optical materials is rapidly moving towards stable, high-power laser sources emitting in the mid-infrared (mid-IR) region...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Cachexia is a condition of involuntary weight loss, undernourishment and a number of negative side-effects that can be seen in patients with Chronic obstructive pulmonary disease (COPD), as well as in cancer and in several severe inflammatory diseases, such as AIDS, congestive heart failure, tuberculosis and rheumatoid arthritis...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
In a notice from the FDA, the Prescription Drug User Fee Act date for its Priority Review of telotristat etiprate has been extended by three months...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Obinutuzumab with bendamustine is used to treat follicular lymphoma in people who did not respond to, or whose condition has progressed after treatment...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
CUVITRU is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body's immune system is missing or functions improperly...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Mino-Lok is being developed as an adjunctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI)...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
APX001 is a small molecule drug candidate that targets and inhibits the conserved fungal enzyme Gwt1, compromising fungal growth of major fungal pathogens...
19 September 2016 | By ABITEC Corporation
ABITEC Corporation continues to add new innovations and dosage form applications to their already expansive product portfolio...
16 September 2016 | By PCI Pharma Services
Leading pharmaceutical provider PCI Pharma Services will bring its expertize to the stage at CPHI Worldwide (Barcelona, October 4-6 2016) with two Speakers Corner slots at the ICSE Exhibitor Showcase...
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis...
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
EB-101 is the company's lead gene therapy program for patients suffering with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of...
